Form 4: MaxCyte Director Patrick Balthrop Receives Future Equity Grant Under Company Policy

MaxCyte, Inc. Director Patrick J. Balthrop was granted 29,210 restricted stock units and 50,790 stock options, effective June 18, 2025, as part of the company's non-employee director equity policy.

Summary

• Patrick J. Balthrop, a Director of MaxCyte, Inc. (MXCT), was granted equity awards as part of his compensation.
• The awards include 29,210 Restricted Stock Units (RSUs) and 50,790 stock options.
• The transaction date for these grants is June 18, 2025, indicating a pre-scheduled award under a Rule 10b5-1 plan.
• Each RSU represents a contingent right to receive one share of MaxCyte's Common Stock and will vest on June 18, 2026, subject to Mr. Balthrop's continuous service.
• The stock options have an exercise price of $2.11 per share and are set to expire on June 17, 2035.
• These grants were made pursuant to MaxCyte's established Equity Grant Policy for non-employee directors.
• Following these transactions, Mr. Balthrop beneficially owns 50,577 shares of Common Stock and 50,790 stock options.

Sentiment

Score: 6

Explanation: The document reports a routine, pre-scheduled equity grant to a director, which is a standard compensation practice. It is mildly positive as it aligns the director's interests with the company's long-term performance, but it is not a significant market-moving event or an indicator of specific operational performance.

Positives

• The grant of 29,210 Restricted Stock Units (RSUs) and 50,790 stock options to Director Patrick J. Balthrop aligns his interests with shareholders by increasing his equity stake in the company.
• The awards are part of the Issuer's established Equity Grant Policy for non-employee directors, indicating a structured and transparent approach to executive compensation.

Future Outlook

The document indicates future vesting of Restricted Stock Units on June 18, 2026, contingent on the director's continuous service, and the expiration of stock options on June 17, 2035. These are standard terms for equity compensation.

Industry Context

This Form 4 filing reflects a routine equity compensation practice for non-employee directors, which is a common mechanism across many publicly traded companies to align director incentives with long-term shareholder value and retain talent.

Corporate Governance

Related Party Transactions

• The equity grants to Director Patrick J. Balthrop constitute a related party transaction, as they involve compensation from MaxCyte, Inc. to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grants align the director's financial interests with those of the shareholders, potentially incentivizing long-term value creation and strategic decision-making.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• Continued service of Patrick J. Balthrop as a director until at least June 18, 2026, for the vesting of the Restricted Stock Units.

Key Dates

Keywords

MaxCyte, MXCT, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Patrick J. Balthrop, Corporate Governance, Rule 10b5-1